CLAIMS

1. A swallowable tablet comprising at least 80% by weight of N-acetylcysteine and at least one pharmaceutically acceptable excipient selected from the group comprising binders, diluents, disintegrating agents, lubricants and glidants, characterized in that the said tablet is manufactured using a granulate prepared by a process of the dry granulation of N-acetylcysteine alone, and wherein said tablet comprises a granulate of N-acetylcysteine alone, at least one binder in a quantity of 5% or more, at least one diluent in a quantity of 5% or more, at least one disintegrating agent in a quantity of 5% or more, at least one lubricant in a quantity of 1% or less, at least one glidant in a quantity of 1% or less, by weight with respect to the total weight of the tablet.

2. The tablet as claimed in claim 1, in which the said binders are selected from the group comprising hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC), polyethylene glycol (PEG), methyl cellulose (MC), povidone (PVP), modified starches and others.

3. The tablet as claimed in claim 1, in which the said disintegrating agents are selected from the group comprising crospovidone, sodium croscarmellose, sodium starch glycolate, partly pregelatinized starch and others.

4. The tablet as claimed in claim 1, in which the said lubricants are selected from the group comprising Ca stearate, Mg stearate, sodium stearyl fumarate, stearic acid and others.

5. The tablet as claimed in claim 1, in which the said glidants are selected from the group comprising anhydrous colloidal silica, talc and others.

6. The tablet as claimed in claim 1, in which the said diluents are selected from the group comprising microcrystalline cellulose (MCC), anhydrous lactose or lactose monohydrate, pregelatinized starch, mannitol, isomaltose, sorbitol and similar carbohydrates, anhydrous dicalcium phosphate or dicalcium phosphate dihydrate, maltodextrin and others.

7. The tablet as claimed in claim 1, the said tablet comprising at least one binder selected from the group comprising hydroxypropyl cellulose, hydroxypropylmethyl cellulose or polyethylene glycol; at least one diluent selected from the group comprising microcrystalline cellulose, mannitol, isomaltose or sorbitol; at least one disintegrating agent selected from the group comprising crospovidone or sodium croscarmellose; at least one lubricant selected from the group comprising Ca stearate, Mg stearate or sodium stearyl fumarate and at least one glidant selected from the group comprising anhydrous colloidal silica or talc.

8. The tablet as claimed in any one of the preceding claims, in which the said tablet comprises a quantity of N-acetylcysteine between 400 mg and 600 mg.

9. The tablet as claimed in claim 8, in which the said tablet comprises a quantity of 600 mg of N-acetylcysteine.

10. The tablet as claimed in claim 8 or 9, for use in patients suffering from CB and/or COPD.

11. The tablet as claimed in claim 10, in which the patients are of the female sex.

12. A process for the preparation of a swallowable tablet according to claim 1, characterized in that the said process comprises (a) a

granulation stage, in which an N-acetylcysteine granulate is obtained by the dry granulation of N-acetylcysteine alone, (b) a mixing stage in which the N-acetylcysteine granulate obtained in stage (a) is mixed with the said binders, diluents, disintegrating agents, lubricants and glidants, and (c) a compression stage in which the mixture obtained in stage (b) is compressed in the said tablet compressor.